LBPH
Longboard Pharmaceuticals, Inc. [LBPH] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LBPH Stock Summary
In the News
LBPH Financial details
Company Rating
Sell
Market Cap
691.53M
Income
-53.92M
Revenue
0
Book val./share
1.71
Cash/share
2.03
Dividend
-
Dividend %
-
Employees
50
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-11.07
Forward P/E
-
PEG
19.85
P/S
-
P/B
10.61
P/C
8.87
P/FCF
-11.32
Quick Ratio
8.35
Current Ratio
8.69
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
-2.37
EPS next Y
-
EPS next Q
-
EPS this Y
-4.78%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.55%
-
-
-
-
SMA20
-6.86%
SMA50
-13.97%
SMA100
307.73%
Inst Own
41.71%
Inst Trans
0.59%
ROA
-85%
ROE
-82%
ROC
-1.01%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.6-28.15
52W High
-35.68%
52W Low
+500.33%
RSI
43.77
Rel Volume
0.81
Avg Volume
618.07K
Volume
502.21K
Perf Week
-3.07%
Perf Month
-10.75%
Perf Quarter
229.85%
Perf Half Y
242.4%
-
-
-
-
Beta
1.255
-
-
Volatility
1%, 1.1%
Prev Close
5.94%
Price
18.01
Change
-1.42%
LBPH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | |
| Net income per share | -0.82 | -1.62 | -2.51 | -2.39 | |
| Operating cash flow per share | -0.19 | -1.45 | -2.22 | -2.24 | |
| Free cash flow per share | -0.19 | -1.45 | -2.22 | -2.24 | |
| Cash per share | 3.13 | 6.25 | 3.94 | 2.13 | |
| Book value per share | 3.01 | 6.05 | 3.58 | 1.8 | |
| Tangible book value per share | 3.01 | 6.05 | 3.58 | 1.8 | |
| Share holders equity per share | 3.01 | 6.05 | 3.58 | 1.8 | |
| Interest debt per share | 0 | 0.03 | 0.09 | 0.02 | |
| Market cap | 294.16M | 83.3M | 55.91M | 137.04M | |
| Enterprise value | 238.84M | 17.48M | 45.88M | 123.18M | |
| P/E ratio | -20.43 | -3 | -1.3 | -2.52 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | |
| POCF ratio | -85.46 | -3.37 | -1.47 | -2.69 | |
| PFCF ratio | -85.46 | -3.37 | -1.47 | -2.69 | |
| P/B Ratio | 5.54 | 0.81 | 0.91 | 3.35 | |
| PTB ratio | 5.54 | 0.81 | 0.91 | 3.35 | |
| EV to sales | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -16.59 | -0.63 | -1.02 | -2.17 | |
| EV to operating cash flow | -69.39 | -0.71 | -1.21 | -2.42 | |
| EV to free cash flow | -69.39 | -0.71 | -1.21 | -2.42 | |
| Earnings yield | -0.05 | -0.33 | -0.77 | -0.4 | |
| Free cash flow yield | -0.01 | -0.3 | -0.68 | -0.37 | |
| Debt to equity | 0 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0 | 0 | 0.01 | 0.01 | |
| Net debt to EBITDA | 3.84 | 2.36 | 0.22 | 0.24 | |
| Current ratio | 17.66 | 19.91 | 7.97 | 5.14 | |
| Interest coverage | 0 | 0 | -53.52 | 0 | |
| Income quality | 0.24 | 0.89 | 0.87 | 0.93 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -16 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | |
| Graham number | 7.42 | 14.87 | 14.23 | 9.85 | |
| ROIC | -0.27 | -0.27 | -0.7 | -1.36 | |
| Return on tangible assets | -0.26 | -0.25 | -0.61 | -1.07 | |
| Graham Net | 2.95 | 5.92 | 3.41 | 1.7 | |
| Working capital | 52.23M | 102.94M | 61.07M | 40.45M | |
| Tangible asset value | 53.1M | 103.32M | 61.47M | 40.92M | |
| Net current asset value | 52.23M | 102.76M | 60.69M | 40.45M | |
| Invested capital | 0 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 1.12M | 1.17M | 1.16M | |
| Average inventory | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 375.22K | 95.63K | 73.07K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | |
| ROE | -0.27 | -0.27 | -0.7 | -1.33 | |
| Capex per share | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.64 | -0.54 | -0.65 | -0.55 | -0.63 | |
| Operating cash flow per share | -0.56 | -0.64 | -0.59 | -0.57 | -0.46 | |
| Free cash flow per share | -0.56 | -0.64 | -0.59 | -0.57 | -0.46 | |
| Cash per share | 3.93 | 3.73 | 2.74 | 2.38 | 2.03 | |
| Book value per share | 3.57 | 3.53 | 2.53 | 2.22 | 1.71 | |
| Tangible book value per share | 3.57 | 3.53 | 2.53 | 2.22 | 1.71 | |
| Share holders equity per share | 3.57 | 3.53 | 2.53 | 2.22 | 1.71 | |
| Interest debt per share | 0.07 | 0.01 | 0.03 | 0.02 | 0.02 | |
| Market cap | 56.1M | 81.84M | 168.59M | 130.59M | 144.27M | |
| Enterprise value | 46.07M | 57.41M | 149.68M | 107.18M | 130.41M | |
| P/E ratio | -1.28 | -1.87 | -2.81 | -2.52 | -2.4 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -5.8 | -6.25 | -12.53 | -9.83 | -13.08 | |
| PFCF ratio | -5.8 | -6.25 | -12.53 | -9.83 | -13.08 | |
| P/B Ratio | 0.91 | 1.13 | 2.9 | 2.51 | 3.53 | |
| PTB ratio | 0.91 | 1.13 | 2.9 | 2.51 | 3.53 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -3.93 | -4.8 | -9.57 | -7.89 | -8.37 | |
| EV to operating cash flow | -4.76 | -4.38 | -11.13 | -8.07 | -11.83 | |
| EV to free cash flow | -4.76 | -4.38 | -11.13 | -8.07 | -11.83 | |
| Earnings yield | -0.2 | -0.13 | -0.09 | -0.1 | -0.1 | |
| Free cash flow yield | -0.17 | -0.16 | -0.08 | -0.1 | -0.08 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 0.86 | 2.04 | 1.21 | 1.72 | 0.89 | |
| Current ratio | 7.97 | 10.91 | 8.3 | 8.69 | 5.14 | |
| Interest coverage | -29.99 | 23.64 | 0 | 0 | 0 | |
| Income quality | 0.85 | 1.14 | 0.9 | 1.03 | 0.73 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.16 | 6.53 | 6.1 | 5.24 | 4.92 | |
| ROIC | -0.18 | -0.16 | -0.25 | -0.26 | -0.36 | |
| Return on tangible assets | -0.16 | -0.14 | -0.23 | -0.22 | -0.3 | |
| Graham Net | 3.4 | 3.36 | 2.39 | 2.09 | 1.62 | |
| Working capital | 61.07M | 71.72M | 57.69M | 51.61M | 40.45M | |
| Tangible asset value | 61.47M | 72.13M | 58.11M | 52.04M | 40.92M | |
| Net current asset value | 60.69M | 71.41M | 57.48M | 51.5M | 40.45M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 942.5K | 796.5K | 1.11M | 1.15M | 682K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 117.9K | 25.47K | 87.26K | 32.67K | 90.09K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.18 | -0.15 | -0.26 | -0.25 | -0.37 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
LBPH Frequently Asked Questions
What is Longboard Pharmaceuticals, Inc. stock symbol ?
Longboard Pharmaceuticals, Inc. is a US stock , located in La jolla of Ca and trading under the symbol LBPH
What is Longboard Pharmaceuticals, Inc. stock quote today ?
Longboard Pharmaceuticals, Inc. stock price is $18.01 today.
Is Longboard Pharmaceuticals, Inc. stock public?
Yes, Longboard Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 618.07K
- Market Capitalization 691.53M
- Employee 50
- CEO Mr. Kevin R. Lind
- Headquarters La Jolla,CA,US
- IPO Date 2021-03-12
-
Website
https://www.longboardpharma.com 
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
